Colorectal Cancer (CRC)
Cancer epidemiology data indicates that worldwide, CRC has the third largest incidence and is the fourth largest killer. Only in 2012, almost 1,4 million persons were diagnosed worldwide and 694 thousand persons have died due to CRC. The current standard of care is still surgery, chemotherapy, radiotherapy and drugs that target angiogenesis or epithelial growth factor receptor (EGFR). 
Mantis Therapeutics has developed an immunotherapy based on conditional attenuated Salmonella vector, that targets CRC and contributes to kill the tumor.
Mantis Therapeutics has generated proof of concept in pre-clinical models demonstrating that our immunotherapy is efficacious against CRC.
Renal cell carcinoma
Renal cell cancer incidence rates vary substantially worldwide. Rates are generally high in Europe and North America and low in Asia and South America. In the USA alone, it is estimated that in 2016 there will be 62,700 new cases of kidney and renal pelvis cancer and an estimated 14,240 people will die of this disease.
Mantis Therapeutics has pre-clinical data that indicates that our targeted immunotherapy is efficacious against renal cell carcinoma.